01-08-2026
Dr.Reddy's Biologics receives its first USFDA Approval
Receives U.S. FDA Approval for Rituximab Biosimilar after successful Pre-License Inspection (PLI) of it's Bachupally facility conducted by U.S. FDA
News
Read More
20-02-2026
Dr. Reddy’s Announces USFDA Acceptance to Review Its Biologics License Application (BLA) for Proposed Interchangeable Biosimilar, Abatacept
Read More
23-09-2025
Dr Reddy’s receives positive CHMP opinion from EMA for AVT03, a proposed biosimilar of Prolia and Xgeva
Read More
10-08-2025
Dr. Reddy’s Hematology Division has received the prestigious Stellar Research Award from the National Medical Forum – New Delhi, honouring excellence in medical research.
Read More
07-06-2025
Alvotech and Dr. Reddy’s to co-develop biosimilar candidate to Keytruda® (pembrolizumab)
Read More
06-02-2025
Dr. Reddy’s enters into collaboration with Henlius for commercialization of HLX15 (daratumumab), a biosimilar candidate to Darzalex & Darzalex Faspro in the U.S., and Europe
Read More
08-12-2024
Dr. Reddy's receives positive CHMP opinion from EMA for its proposed Rituximab biosimilar
Read More
28-11-2024
Dr Reddy's launches novel cancer therapy Toripalimab in India
Read More
29-07-2024
Dr. Reddy's rituximab biosimilar ituxredi gets EMA CHMP positive recommendation
Read More
29-07-2024
Dr Reddy’s gets positive opinion from EMA for its rituximab biosimilar
Read More
Naidu Seepana
Clinical Dev.
Vijayender
Engineering
Anjaneyulu V
Warehouse
S Appalanaidu
Engineering
Pinakin Patel
PPM
Bricks of Biologics, appreciates the contribution and celebrates our people who are the building blocks of Dr. Reddy's Biologics.
Bricks of biologics in general refers to bio-bricks as genetic building blocks which are DNA sequences that can be assembled to create complex biological systems.